Newswire (Published: Friday, September 13, 2019, Received: Friday, September 13, 2019, 5:28:36 PM CDT)
Word Count: 497
2019 SEP 13 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Daily -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating in Salt Lake City, United States, by NewsRx journalists, research stated, “Targeted therapies have shown promise for men with metastatic castration-resistant prostate cancer (mCRPC). Due to the difficulty with obtaining tumor tissue in bony metastases, liquid biopsies are a promising alternative to guide treatment selection.”
Financial supporters for this research include Pfizer, Janssen Pharmaceuticals, Merck, GlaxoSmithKline, Prometheus, Eisai, Novartis, Celldex Therapeutics, Sanofi, Exelixis.
The news reporters obtained a quote from the research from the University of Utah, “While concurrent tissue next-generation sequencing (tNGS) and liquid biopsy has high concordance, it is unknown whether the genomic landscape of metastatic prostate cancer (mPC) changes over time or treatment. Herein, we hypothesize that the genomic landscape of mPC evolves with new treatments and/or time between tests. Men with mPC from the University of Utah with matched tNGS and liquid biopsy were included. Clinical data was collected retrospectively. Exonic regions from 69 genes covered by both platforms were included for analysis. Paired t tests were used to assess number of genomic alterations (GAs) between testing platforms. Number of alterations was assessed by time and number of treatments between testing by multivariate nonparametric trend tests. 101 men with mPC were eligible and included. In men with no new treatments and 1 year between tests, a similar number of GAs were detected in both tests (2.0 vs. 2.2). In contrast, men with 1 new treatment between tests had significantly more GAs after treatment (5.0 vs. 2.4, p=0.005). Total number of GAs was correlated with number of new treatments between testing (p=0.003) and not time between testing (p=0.76). The genomic landscape of mPC evolves with subsequent therapies.”
According to the news reporters, the research concluded: “This finding suggests that contemporary tumor genomic profile upon disease progression may optimize guidance towards subsequent therapy selection.”
For more information on this research see: Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treatment and Research Communications, 2019;19():100120.
Our news correspondents report that additional information may be obtained by contacting N. Agarwal, Division of Oncology, Dept. of Internal Medicine, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive Suite 5726, Salt Lake City, UT 84112, United States. Additional authors for this research include D. Stenehjem, R. Nussenzveig, E. Carroll, E. Bailey, J. Batten, B.L. Maughan and N. Agarwal.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.ctarc.2019.100120. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Janssen Pharmaceuticals Inc
Johnson & Johnson
Eisai Co. Ltd.
Eisai Co. Ltd.
Celldex Therapeutics Inc.
The University of Utah
N. Dylan & Co. LLC
Salt Lake City
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Functional and Comparative Genomics
Treatments and Therapies